Enorama Pharma AB (ERMA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Enorama Pharma AB (ERMA) has a cash flow conversion efficiency ratio of 0.330x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-12.09 Million ≈ $-1.30 Million USD) by net assets (Skr-36.63 Million ≈ $-3.94 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Enorama Pharma AB to measure how much of total assets are equity-financed.
Enorama Pharma AB - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Enorama Pharma AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ERMA cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Enorama Pharma AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Enorama Pharma AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NT Minerals Ltd
AU:NTM
|
-0.063x |
|
1844 Resources Inc
V:EFF
|
0.136x |
|
Datadot Technology Ltd
AU:DDT
|
-0.008x |
|
Arkha Jayanti Persada PT
JK:ARKA
|
0.000x |
|
Galore Resources Inc
V:GRI
|
0.009x |
|
Pensana Rare Earths Plc
LSE:PRE
|
-0.003x |
|
iTonic Holdings Ltd.
NASDAQ:ITOC
|
-0.050x |
|
Providence Gold Mines
V:PHD
|
0.002x |
Annual Cash Flow Conversion Efficiency for Enorama Pharma AB (2014–2025)
The table below shows the annual cash flow conversion efficiency of Enorama Pharma AB from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Enorama Pharma AB.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr-23.45 Million ≈ $-2.52 Million |
Skr-59.26 Million ≈ $-6.38 Million |
2.527x | +155.23% |
| 2024-12-31 | Skr7.80 Million ≈ $839.73K |
Skr-35.70 Million ≈ $-3.84 Million |
-4.575x | -116.20% |
| 2023-12-31 | Skr19.54 Million ≈ $2.10 Million |
Skr-41.35 Million ≈ $-4.45 Million |
-2.116x | -102.43% |
| 2022-12-31 | Skr31.52 Million ≈ $3.39 Million |
Skr-32.96 Million ≈ $-3.55 Million |
-1.045x | +25.99% |
| 2021-12-31 | Skr21.35 Million ≈ $2.30 Million |
Skr-30.16 Million ≈ $-3.25 Million |
-1.413x | +89.09% |
| 2020-12-31 | Skr1.78 Million ≈ $191.23K |
Skr-23.00 Million ≈ $-2.47 Million |
-12.942x | -249.80% |
| 2019-12-31 | Skr7.18 Million ≈ $772.64K |
Skr-26.56 Million ≈ $-2.86 Million |
-3.700x | -371.31% |
| 2018-12-31 | Skr17.02 Million ≈ $1.83 Million |
Skr-13.36 Million ≈ $-1.44 Million |
-0.785x | +13.32% |
| 2017-12-31 | Skr7.36 Million ≈ $792.18K |
Skr-6.67 Million ≈ $-717.43K |
-0.906x | -34.48% |
| 2016-12-31 | Skr9.08 Million ≈ $977.10K |
Skr-6.11 Million ≈ $-658.02K |
-0.673x | -1015.31% |
| 2015-12-31 | Skr6.52 Million ≈ $702.09K |
Skr480.00K ≈ $51.66K |
0.074x | -36.25% |
| 2014-12-31 | Skr2.66 Million ≈ $286.26K |
Skr307.00K ≈ $33.04K |
0.115x | -- |
About Enorama Pharma AB
Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum in Sweden. It offers nicotine chewing gum and nicotine pouches under the NIC-S brand name. The company was incorporated in 2006 and is based in Malmö, Sweden.